Skip Navigation
Search

Transcatheter Aortic Heart Valve Replacment (TAVR) Research

Numerical and Benchtop Evaluations and Development of TAVR Valve Devices and Procedures

CAVD and TAVR illustrations

  • Calcific aortic valve disease is a cardiovascular condition that causes the progressive narrowing of the aortic valve (AV) opening, due to the growth of bone-like deposits all over the aortic root (AR).
  • Transcatheter aortic valve replacement (TAVR) is a minimally invasive procedure that has recently become the only lifesaving solution for patients that cannot tolerate the standard surgical valve replacement.
  • This technique comprises of a prosthetic valve mounted on a stent and deployed inside the pathologic native valve.

Patient-specific In-Vitro Models for TAVR Performance Evaluation

Traditionally, TAVR valves are benchmarked and evaluated with the ISO 5840 standard, which was originally designed for surgical valve testing, and negates key anatomical features of aortic stenosis patients. The interaction between the TAVR stent frame and the unique/ irregular calcific masses inside the patient leaflets define the deployed shape and therefore the functionallity of the valve.
The goal of this research was to develop a patient-specific replica of calcific aortic valve disease(CAVD) to emulate the expected clincial performance of the TAVR devices. In collaboration with Vascular Simulations, we developed such a model to interface with the advanced simulation system called the Replicator Pro, which allows us to study various patient anatomies inside the cath-lab as if it was a patient on the table. We can rapidly deploy, measure and image the valves for clinical evaluations as well as develop more adavanced imaging techniques such as an intra-procedural CT for measure the coaption of the stent to the replica lumen.

invitro TAVR graphical abstract
Two different TAVR devices, one self-expandable polymeric and one balloon-expandable tissue valve, were evaluated according to the ISO 5840 guidelines but in five different patient models. The patient-specfic results were compared to the idealized geometry simulator commonly used in ISO 5840 testing, and we showed that the current standards can dramitically overestimate the performance of the valves.
Evolving from in-vitro models to in-silico simulations

In order to study the resulting paravalvular leak flows in greater detail, we developed a protocol to µCT scan the deployed TAVR devices inside the CAVD replicas. Segmentation of the deployed geometry yeilds an ideal numerical domain to perform detailed CFD analysis (ANSYS Fluent) on the leak flows.

 

Lastly platelet-like particles are seeded with a DPM model in the ventricle geometry and tracked for 3 cycles. Showing the first evidence of the possiblity of platelet to enter the PVL domain during systole and the potential of repeated reincorporation into the PVL flows over the successive cycles.

 
Patient-Specific numerical simulations for studying clinical complications

Do to the interaction of the TAVR stent frame and the characteristic unique structures of the calcific leaflets in aortic stenosis patients, patient-specific modelling and simulation is vital to understand the mechanics of the procedure. During and after the procedure clinical complications, such as AR injury, paravalvular leakage (PVL) and migration of the device may occur and lead to surgical failure, in situ. Our current research aims at evaluating the effect of different TAVR devices, deployment scenarios/positions on the device anchorage to the native AR using patient-specific numerical models.

TAV patient model deployment

Finite element analysis allows for the structural/mechanics study of the metallic stent frame as it interacts and contacts the hyper-elastic tissues of the patient geometry, allowing accurate study of anchorage forces of the TAVR. This would allow for informing clinicians on the optimal deployment configuration for a specific patient, which is currently not possible to study in situ.

After the structural simulations are completed, the fluid domain can be extracted and computation fluid dynamics is used to study the paravalvular leak flows between the stent and the native leaflets/lumen.
These flow patterns can be compared to clinical images, with excellent agreement between the location of PVL in the numerical models to the color doppler images acquired from the patient.

DPM PVL particle seeding

Utilizing the established flow patterns in the CFD model, platelet-like particles are seeded in the aorta and with a discrete phase model (DPM), the particle stress accumulations are tracked while washing through the PVL channels.

Looking at the stress accumulation (SA) of each particle and comparing the models with a probablity density function (PDF), we can tell which deployment scenario results in the largest increase in thrombogenic potential.

Fluid-Structure Interaction (FSI) Simulations of TAVR

FSI Analysis of TAVR Valve Performances in Living Heart

LHHMis an electro-mechanical model of heart function in which a self-expandable TAVR valve (Evolut R; Medtronic, Inc.) implantation procedures were simulated using finite element modeling (Abaqus Explicit 6.14; Dassault Systèmes). Three implantation depth locations (aortic, midway, and ventricular) following the manufacturer guidelines were modeled to study the valve anchorage. The anchorage was evaluated based on the calculated contact area between the stent’s outer frame with the native CAV over time. The deformed TAVR stent equipped with the prosthetic leaflets and LHHM anatomy were extracted for FSI simulation to assess and quantify the valve hemodynamics parameter, PVL degree, and thrombogenicity. A 2-way implicit coupling(FlowVision Multi-Physics Manager 3.10; Capvidia)was used between a finite-volume based body-fitted sub-grid geometry resolution method (FlowVision 3.10) and a finite element solver (Abaqus Explicit 6.14) during the FSI analysis fluid and structural solution, respectively.

Polymeric TAVR Valve Evaluation
Our research group recently adapted the Polynova polymeric surgical valve (Polynova Cardiovascular Inc., Stony Brook, NY) design for TAVR procedures.

Our current research aims at evaluating this novel polymeric valve by comparing its crimping mechanics and thrombogenic potential with commercially available TAVR valves. This has been pursued via a Finite Element Analysis to examine the leaflets structural integrity in their crimped configurations, and via a fully coupled Fluid-Structure Interaction (FSI) to investigate their systolic hemodynamics and thrombogenicity.

TAVR in Bicuspid Aortic Valve Anatomies

  • Bicuspid aortic valve (BAV) is the most common congenital heart disease, affecting 0.40% to 2.25% of general population
  • Associated complications –early onset of calcific aortic valve disease (CAVD), aortic stenosis (AS), and regurgitation and impaired hemodynamics
  • BAV patients had systematically been excluded from clinical trials comparing the performance between TAVR and SAVR due to inherent structural asymmetry and severe leaflet calcification in BAV patients, and resulting distorted deformation profile of the TAVR device
  • TAVR is recently being adapted for off-label use to treat BAV patients
  • Despite of showing promising performances, the post TAVR complications combined with the inherent structural complexity in the BAV patients, are preventing the establishment of TAVR as standard care for BAV patients
 

BAV anatomy

In-silico Evaluation

Our current work is focusing on developing patient-specific finite element (FE) models of TAVR procedure in a BAV patients to investigate post-procedural complications and feasibility of each device design.
Additionally, post-deployment computational fluid dynamics models are created utilizing the deformed geometry resolved in the FE models. The fluid simulation allows us to characterize the large paravalvular leaks that are often exacerbated in the BAV anatomy.

 
 
In-vitro Evaluation

In-vitro validation of the computational model with 3-D printed replicas, in which these complications will be further assessed and confirmed using post procedural data (onset of cardiac conduction abnormality, degree of paravalvular leakage and so on). This validation includes CT scans of the model to characterize the deformation of the stent as well as flow studies in a left heart simulator to validate the results of the CFD analysis.

 In vitro BAV

 

TAVR Patient Cohort Expansion - Design and Optimization of TAVR Devices for Increased Durability and Long-Term Performance 

In silico Fatigue Optimization of TAVR Stent Designs With Physiological Motion in a Beating Heart Model
  • Expansion of TAVR makes fatigue life and durability crucial to device success
  • Nitinol stents experience cyclic displacements/strains in vivo, yet benchtop stent frame fatigue testing excludes beating heart effects and dynamic loading
  • In silico approaches include beating heart effects, more accurate modeling of TAVR device durability
  • The electro-mechanical SIMULIA Living Heart Human Model of a beating heart allows for virtually deploying devices to analyze displacements, associated strains, tissue stresses and contact forces

  • With this approach, we examined TAVR stent design implications on fatigue outcomes by scaling strut width by 20%

Strut_Strain

  • The primary cause of element failure was strain amplitudes exceeding fatigue limits for nitinol, where the failure threshold was overlaid on fatigue plots to analyze stent elements for each model that had "failed" virtually

Stent_DeformationStrain_Amplitude

  • Our PolyV-2 stent demonstrated superior fatigue resistance when compared to the comemrcial CoreValve and Evolut R stents models, as it was previously optimized to minimize stresses and strains
  •  Localized modes of stent failure highlighted here in current commercial devices demonstrates the utility of intricate in silico models to evaluate stent design for optimization of fatigue resistance
Fatigue_Plot_Comparisons
Mitigating Thrombogenic Risk By Varying Leaflet Design
  • Current TAVR products are stented, bioprosthetic tissue valves whose durability and design is limited (structural damage during crimping)
  • Novel polymers allow for more durable TAVR valves and mitigate current complications as they combine features of engineering flexibility, hemocompatibility, structural integrity and reproducibility
  • TAVR is associated with long-term, life-threatening thrombotic events, a consequence of prolonged exposure of platelets to elevated, cumulative cyclic stresses; increased risk of platelet activation via stress accumulation
Valve_Thrombosis
  • Must develop alternatives to current tissue-based TAVR products as new devices must remain safe and functional for extended periods of time
  • Optimization of polymeric leaflets and valve design can improve hemodynamics and mitigate thrombosis; optimization via geometry changes can be achievedFlow_Chart
  • Virtual commercial TAVR models (26-mm) were generated to match the phsyical devices, while multiple polymeric valve designs (26-mm) were created by varying leaflet attachment and belly curvature
  • With the constructed leaflets and stents, idealized TAVR deployments were generated and FSI analysis was performed for two cardiac cycles, where leaflet kinematics and valve hemodynamics were analyzed
  • Validation of commercial devices via effective orifice area (EOA) and velocity profiles
Device_Design
  • Probability density functions (PDFs) of the accumulated stresses for the flowing platelets were computed for each device (which represents the “thrombogenic footprint” for each respective device), analyze thrombogenic potential of different leaflet designs by comparing PDFs
  • Here, we see the top 100 stress accumulation platelet trajectories colored by stress. In particular, we see the highest stresses near the surfaces of the prosthetic leaflets and at the leaflet tips, demonstrating the key idea that platelets interact differently with varying valve designs and experience different magnitudes of stress during their trajectories as they flow past each prosthetic device
Platelet_Stress_Trajectories
  • Hemodynamics and leaflet kinematics were different for each TAVR design, where designs #1-2 and the SAPIEN3 showed lower peak fluid velocities as compared to the other devices, likely due to these leaflets producing larger orifice areas and having reduced leaflet fluttering, which may be due to more optimal surface area and leaflet inflation
  • The conversion of the data into PDFs also support this when looking at the tail region of the curves, as this region highlights the stress magnitudes that are likely to cause platelet activation. The original stress accumulation data was normalized to time in order to consider the small number of cardiac cycles simulated here. When doing this, the data distribution becomes unbiased and agrees well with the previous flow results since the commercial Evolut R, along with parametric designs #3-5 show the highest thrombogenic risk from the larger PDF tails
PDFs_thrombogenicity
Thrombogenic_Risk_Table
TAVR in BAV Patients - Thrombogenic Risk Analysis 
  • Current commercial TAVR devices often deploy elliptically in BAV patients, resulting in worse TAVR outcomes
  • Our research group developed a polymeric TAVR leaflet design, PolyV-B, that was hypothesized to yield better hemodynamic performance (see TAVR Developement Page)
  • We analyzed thrombogenic risk of this device and compared results to commercial devices currently used to treat BAV patients. Specifically, we modeled the 29-mm Evolut R (EV29) TAVR deployment first with the commercial leaflets in place, and then by replacing the commercial leaflets with our PolyV-B design, all in patient-specific models
PolyVB_EvolutR_Compare
  • The novel design resulted in larger orifice areas and reduced jet velocities, outperforming the commercial Evolut R. The thrombogenicity comparison shows that the PolyV-B design has a smaller thrombogenic footprint when compared to the Evolut R
BAV_patient_thrombogenicity_Comparison
  • In each panel, we see the red curve representing the commercial device was shifted towards higher stress accumulation values in addition to having more pronounced tail regions, increasing the likelihood of activating platelets. This is also indicated in the tabulated data, where the median stress accumulation among the highest or top 100 trajectories was largest for the Evolut R, indicating increased thrombogenic risk

 

Risk Assessment of Post-TAVR Cardiac Conduction Abnormalities Asing A 'Digital Twin' of Human Heart

  • Post-TAVR Cardiac conduction abnormalities (CCAs)  occur due to mechanical damage sustained by the atrioventricular conduction system located near the inter-leaflet triangle region between the non-coronary and the right-coronary leaflet. In his study, we have used an electro-mechanically coupled beating heart model to develop an in-silico technique to assess CCA risk incorporating the effect of a dynamic beating heart and pre-procedural parameters such as implantation depth and preexisting cardiac asynchrony in the development of post-TAVR CCA.

TAVR in LHP

TAVR Deployment in Living Human Heart Model (Electro-mechanically coupled)

Preexisting conduction abnormalities modeling

Preexisting conduction abnormalities modeling

  • Contact pressure, Contact Pressure Index (CPI), and stress components on the area of interest (AOI)  were analyzed for three implantation depths and three preexisting conduction abnormalities scenarios. 
  • Lower implantation, and preexisting-right bundle branch block (RBBB) poses higher risk of post-TAVR CCA which is aligned with the clinical findings.

Publication link- Assessing Post-TAVR Cardiac Conduction Abnormalities Risk Using a Digital Twin of a Beating Heart

 

Effect of Sinotubular Junction Size on TAVR Leaflet Thrombosis

  • TAVR has emerged as a standard approach for treating severe aortic stenosis patients. However, it is associated with several clinical complications, including subclinical leaflet thrombosis characterized by Hypoattenuated Leaflet Thickening (HALT). A rigorous analysis of TAVR device thrombogenicity considering anatomical variations is essential for estimating this risk.
  • In this study, we presented a comprehensive framework to analyze structural analysis of TAVR deployment, hemodynamic analysis via FSI simulation coupled with thrombogenic risk assessment via Lagrangian particle tracking. 

Patient model reconstruction and TAVR deploymentPatient model reconstruction and TAVR deployment

Structural analysis of device eccentricity

Structural analysis of device eccentricity

Hemodynamic analysis of device eccentricity

Hemodynamic analysis 

  • A smaller STJ size impairs adequate expansion of the TAVR stent, which may lead to suboptimal hemodynamic performance.
  • Larger STJ size marginally enhances the hemodynamic performance but increases the risk of TAVR leaflet thrombosis. Such analysis can aid pre-procedural planning and minimize the risk of TAVR leaflet thrombosis.

Publication link- Effect of Sinotubular Junction Size on TAVR Leaflet Thrombosis: A Fluid–Structure Interaction Analysis

 

Feasibility and Performance Analysis of Redo-TAVR

  • Durability remains one of the major concerns for TAVR technology. This evidence of thrombosis and rapid degeneration of prosthetic valves poses a significant risk to the increasing number of young and low-risk TAVR recipients, necessitating repeat intervention. Transcatheter aortic valve-in-transcatheter aortic valve (TAV-in-TAV) or redo-TAVR is being considered as a potential treatment of choice for transcatheter heart valve (THV) degeneration which has shown success in addressing suboptimal outcomes.
  • In this study, we leveraged advanced computational modeling to analyze structural and hemodynamic performance of 4 redo-TAVR combinations and suggested the pros and cons of easch combination.

Redo-TAVR Feasibility Analysis Framework

Redo-TAVR Feasibility Analysis Framework